Methods and Results —Based on the proven efficacy of colchicine therapy for familial Mediterranean fever (recurrent polyserositis), several small studies have used
A decade ago, large trials demonstrated the dramatic effect of colchicine, capable of halving the risk of further recurrences [ 2, 4, 7, 8 ]
54, p for effect <0
The pericardium is not essential—normal cardiac function can be maintained in its absence—however, diseased pericardium presenting clinically as acute or chronic
Recurrent pericarditis is a problematic clinical condition that impairs the quality of life of the affected patients due to the need for repeated hospital admissions
Acute pericarditis should be treated with a nonsteroidal anti-inflammatory drug (NSAID), typically with a 2- to 4-week taper after the resolution of symptoms
Colchicine does not cure gout, but it will help prevent gout attacks
3 The association of aspirin plus colchicine demonstrated a significant
We compared the effects of colchicine in addition to a non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen, aspirin or indomethacin to the effects of the NSAID alone
1 The spectrum of pericarditis consists of acute, incessant, chronic, recurrent, and constrictive pericarditis
Patients diagnosed with acute or recurrent idiopathic pericarditis may suffer significant morbidity due to disease burden or adverse drug reactions
Colchicine is commonly used as part of the treatment of acute and recurrent pericarditis
It also has approval for the treatment of familial Mediterranean fever
If those medications don't help, the next step might be corticosteroids
Colchicine has been shown to be promising for the secondary prevention of recurrent pericarditis in the CORE (recurrent pericarditis), COPE (acute pericarditis) open-label studies, and the CORP (first recurrent pericarditis) trials
doi: 10
Recurrent pericarditis is pericarditis that recurs after a symptom-free interval of at least 4-6 weeks
Medical Professional
Studies investigating ≥ 10 patients with clinically PPS treated with colchicine, dexamethasone, and indomethacin and compared with placebo Studies on ≥ 10 patients with clinical pericarditis or post-pericardiotomy syndrome in which colchicine, dexamethasone, and indomethacin were compared with placebo were included
2005 In a small, early, prospective study, Guindo et al 4 gave colchicine 1 mg/day to patients who had had at least three relapses of acute pericarditis while being treated with aspirin, indomethacin, prednisone, or a combination of these agents